superficial esophageal neoplasms
Conditions
Interventions
A: After local steroid (triamcinolone acetonide 100 mg) injection to the ulcer, prednisolone is started on post-operative day 3 at a dose of 30 mg/day. The administration of steroids was discontinued
Sponsors
Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University
Asahikawa-Kosei General Hospital Asahikawa City hospital Japanese Red Cross Asahikawa Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients over 20 years of age 2)Patients who are histologically proven esophageal squamous cell carcinoma or intraepithelial neoplasia 3)Patients with primary tumor located in the epithelium, lamina propria mucosa, muscularis mucosa or submucosa confirmed by endoscopy 4)Patients with dysphagia score of 0 5)Patients who admit to a hospital 6)Patients with written informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients with prior radiotherapy to the neck, chest wall, lung, or mediastinum 2)Patients with primary tumor located within 20mm from prior EMR/ESD treatment site 3)Patients who fail to pass through the prior EMR/ESD treatment site by a standard endoscope (for the upper gastrointestinal tract) 4)Patients with surgery or radiotherapy for esophagus within 3 months after esophageal ESD 5)Patients who judged inappropriate by an attendant physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| stricture-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| the number of endoscopic balloon dilation for 12 weeks after ESD, adverse events and proportion of patients with dysphagia score=<1 at the time of 12 weeks after ESD | — |
Countries
Japan
Contacts
Public ContactKeitaro Takahashi
Asahikawa Medical University Division of Gastroenterology and Hematology/Oncology, Department of Medicine
Outcome results
None listed